EGFR inhibitors

systematic review meta-analysis network meta-analysis

Select lung cancer (metastatic) All type of patientFirst line2nd line or more       monoclonal antibodyTKI afatinibdacomitinibosimertinib cetuximaberlotinibgefitinib       1st line2nd lineEGFR mutationsmaintenance therapy

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (21)death (overall survival) (18)objective response (ORR) (16) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
lung cancer (metastatic)
afatinib
LUX-LUNG 6, 2015	afatinib	cisplatin-based chemotherapy				-
LUX-LUNG 3, 2015	afatinib	cisplatin-based chemotherapy				-
cetuximab
Lynch, 2010	cetuximab	CT			Risk of bias	negative
Butts, 2007	cetuximab	CT alone				-
Rosell, 2008	cetuximab + CT	CT alone				-
FLEX (Pirker), 2009      NCT	cetuximab + CT	CT alone				suggesting
dacomitinib
ARCHER 1050      NCT	dacomitinib	gefitinib				-
erlotinib
TITAN	erlotinib	Platinum-based CT		2nd line	Risk of bias	negative
EUTRAC	erlotinib	Platinum-based CT		1st line EGFR mutations	Risk of bias	suggesting
OPTIMAL	erlotinib	Platinum-based CT		EGFR mutations	Risk of bias	suggesting
Boutsikou	erlotinib + Platinum-based CT	Platinum-based CT		1st line		negative
SATURN (Cappuzzo)	erlotinib + Platinum-based CT	Platinum-based CT		maintenance therapy		suggesting
Mok	erlotinib + Platinum-based CT	Platinum-based CT		1st line		suggesting
Lee	erlotinib + Platinum-based CT	Platinum-based CT		2nd line		suggesting
Gatzemeier	erlotinib + Platinum-based CT	Platinum-based CT		1st line		negative
TRIBUTE (Herbst)	erlotinib + Platinum-based CT	Platinum-based CT		1st line		negative
Stinchcombe	erlotinib + Platinum-based CT	Platinum-based CT				negative
FASTACT-2 (Wu)	erlotinib + Platinum-based CT	Platinum-based CT		1st line		suggesting
gefitinib
West Japan	gefitinib					-
Northeast Japan	gefitinib					-
CTONG0806 (Yang), 2013	gefitinib					-
NEJ002, 2013	gefitinib	carboplatin-paclitaxel	1L			-
Maemondo, 2010	gefitinib	carboplatin-paclitaxel	2L			-
IPASS (Mok), 2009      NCT	gefitinib	carboplatin-paclitaxel	1L			-
IPASS	gefitinib	carboplatin/paclitaxel	1L			-
WJTOG3405 (Mitsudomi), 2010	gefitinib	cisplatin plus docetaxel				-
WJTOG0203 (Takeda), 2010	gefitinib	continued platinum-doublet chemotherapy				-
IFCT-0301 study (Morère), 2010	gefitinib	docetaxel				-
SIGN (Cufer), 2006	gefitinib	docetaxel	2L			negative
INTEREST (Kim), 2008	gefitinib	docetaxel	2L			negative
V-15-32 (Maruyama), 2008	gefitinib	docetaxel	2L			suggesting
ISTANA (Lee), 2010	gefitinib	docetaxel	2L			suggesting
Kris, 2003	gefitinib	gefitinib	2L		Low risk of bias	-
First Signal	gefitinib	gemcitabine and cisplatin	1L			-
INTACT 2, 2004	gefitinib paclitaxel and carboplatin	paclitaxel and carboplatin	1L		Low risk of bias	-
Goss, 2009	gefitinib	placebo	1L			-
SWOG S0023 (Kelly), 2008	gefitinib	placebo				-
EORTC 08021/ILCP 01/03, 2011      NCT	gefitinib	placebo	2L			-
INFORM; C-TONG 0804, 2012      NCT	gefitinib	placebo				-
NCIC CTG BR19 (Goss), 2013	gefitinib	placebo			Low risk of bias	-
ISEL, 2006	gefitinib	placebo	2L			-
Tsuboi, 2005	gefitinib	placebo				-
INTACT 1.	gefitinib + gemcitabine/cisplatin	placebo + gemcitabine / cisplatin	1L		Low risk of bias	-
INVITE (Crinò), 2008      NCT	gefitinib	vinorelbine	1L			-
osimertinib
FLAURA, 2017      NCT	osimertinib	placebo	1L		Low risk of bias	suggesting
AURA 3, 2017    NCT	osimertinib	platinum-based therapy plus pemetrexed	2L			suggesting